Evidence map›Paper›PMID 32318327›Full record

ArticleActa pharmaceutica Sinica. B2020

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.

Xiaoyan Liu, Zhe Li, Shuai Liu, Jing Sun, Zhanghua Chen, Min Jiang, Qingling Zhang, Yinghua Wei, Xin Wang, Yi-You Huang and 15 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 5 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 5 syntheses or guidelines pooled it, 238 citations in OpenAlex.

  1. Pooled it
  2. The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review.International journal of molecular sciences · 2021
    Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Post-COVID Mucormycosis-Conceptual Etiology and New Treatment Options.Journal of maxillofacial and oral surgery · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Screening for Active Compounds ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. The role of cell death in SARS-CoV-2 infection.Signal transduction and targeted therapy · 2023
    Review

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 3 countries.

Xiaoyan LiuDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zhe LiGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Shuai LiuDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Jing SunState Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Zhanghua ChenGuangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China.
Min JiangDepartment of Infectious Disease and Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Qingling ZhangState Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Yinghua WeiDepartment of Infectious Disease and Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Xin WangCenter for Innovative Marine Drug Screening & Evaluation (QNLM), School of Medicine and Pharmacy, Ocean University of China, Qingdao 266100, China.
Yi-You HuangGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Yinyi ShiDawu County People's Hospital, Xiaogan 432826, China.
Yanhui XuGuangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China.
Huifang XianGuangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China.
Fan BaiBiomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing 100871, China.
Changxing OuState Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Bei XiongDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Andrew M LewWalter and Eliza Hall Institute of Medical Research and Department of Microbiology & Immunology, University of Melbourne, Parkville, Vic 3052, Australia.
Jun CuiSchool of Life Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Rongli FangGuangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China.
Hui HuangCardiovascular Department, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China.
Jincun ZhaoState Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Xuechuan HongState Key Laboratory of Virology, College of Science, Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Medical College, Tibet University, Lhasa 850000, China.
Yuxia ZhangGuangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China.
Fuling ZhouDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Hai-Bin LuoGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
First Affiliated Hospital of Guangzhou Medical University · CNSun Yat-sen University · CNWuhan University · CNState Key Laboratory of Respiratory Disease · CNGuangxi Medical University · CNPeking University · CNDawu County People's Hospital · CNOcean University of China · CNThe University of Melbourne · AUTibet University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP)

Indexed as

COVID-19D-dimerDipyridamoleSARS-CoV-2Severe casesTreatment

Identifiers

PMID32318327
PMCPMC7169892
OpenAlexW3016961971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.